FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
Rhea-AI Summary
FendX (OTCQB: FDXTF) filed a provisional patent application with the US Patent and Trademark Office for an "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces" (application no. 63/936,328), filed August 7, 2025, with FendX as assignee.
The application, prepared by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, describes a novel nanoparticle liquid coating engineered for easy application (roller or brush) to actively disrupt microbial contamination and provide sustained protection on high-touch surfaces. The company said it is assessing scale-up and distribution partnership opportunities to commercialize the technology.
Positive
- None.
Negative
- None.
News Market Reaction – FDXTF
On the day this news was published, FDXTF gained 12.17%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces", assigned application number 63/936,328, was filed on August 7, 2025, by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, with FendX as the assignee. This filing marks a significant addition to the Company's expanding portfolio of hygiene-related technologies.
The new application describes a novel nanoparticle liquid coating (formerly described as the spray technology) designed to provide long-lasting protection against a broad spectrum of pathogens found on high-touch surfaces. Engineered for easy application, using for example, a roller or brush, the coating leverages nanoparticle technology to actively disrupt microbial contamination, offering sustained efficacy in multiple settings.
"We are pleased with the progress of our development efforts on this liquid coating technology which have resulted in the filing of this patent application," said Dr. Carolyn Myers, CEO of FendX. "We are now actively assessing scale-up and distribution partnership opportunities to bring this technology to the market. This innovation underscores FendX's commitment to developing scalable solutions aimed at reducing infection risk."
About FendX Technologies Inc.
FendX is a surface protection company leveraging its proprietary technology to develop product solutions that help reduce the spread of harmful pathogens in everyday environments. The Company is advancing its pipeline of products under development which includes REPELWRAP™ film, a protective surface coating with repelling properties that significantly reduce adhesion and transmission of pathogens on high-touch surfaces, and nanoparticle infused liquid coating with similar functionality. Additionally, the Company is developing specialized catheter coatings, with its first coating being for Foley catheters. The Company holds exclusive worldwide licenses and intellectual property for its coating technologies.
ON BEHALF OF THE COMPANY
"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the provisional patent application, the nanoparticle liquid coating technology, including the proposed easy application methods using for example a roller or brush, the proposed benefits of, efficacy and goals related to the development of the technology; statements regarding the Company actively assessing scale-up and distribution partnership opportunities to bring this technology to the market; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the provisional patent application may not receive regulatory approval; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities including development and scale-up of the nanoparticle liquid coating; risks related to research and development activities for each of the film, nanoparticle liquid coating formulation and catheter coating, including successful completion of real world performance testing and scale-up initiatives; risks that the Company may not expand its product pipeline or execute its business development and growth plans; risks that the Company will be unsuccessful in entering into distribution partnerships to market its products; risks that the Company's products may not be commercialized, and if they are commercialized, that they may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; product candidates only being in formulation/reformulation stages; limited operating history; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271383
FAQ
What did FendX (FDXTF) file on August 7, 2025?
Who are the inventors listed on FendX's provisional patent for the coating?
What does the FendX (FDXTF) patent application describe?
How might the provisional patent filing affect FendX shareholders (FDXTF)?
Is FendX (FDXTF) ready to commercialize the nanoparticle coating now?
Where was FendX's provisional patent filed and what is its title?
